The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth

被引:184
作者
Cadwell, C [1 ]
Zambetti, GP [1 ]
机构
[1] St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA
关键词
mgain-of-function; trans activation; apoptosis and tumorigenicity;
D O I
10.1016/S0378-1119(01)00696-5
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
The tumor suppressor p53 plays a central role in the protection against DNA damage and other forms of physiological stress primarily by inducing cell cycle arrest or apoptosis. Mutation of p53, which is the most frequent genetic alteration detected in human cancers, inactivates these growth regulatory functions and causes a loss of tumor suppressor activity. In some cases, mutation also confers tumor-promoting functions, such as the transcriptional activation of genes involved in cell proliferation, cell survival and angiogenesis. Consequently, cells expressing some forms of mutant p53 show enhanced tumorigenic potential with increased resistance to chemotherapy and radiation. Our current understanding of these activities is summarized in this review. By dissecting out mechanistic differences between wild-type and mutant p53 activities, it may be possible to develop therapeutics that restore tumor suppressor function to mutant p53 or that selectively inactivate mutant p53 tumor-promoting functions. (C) 2001 Published by Elsevier Science B.V.
引用
收藏
页码:15 / 30
页数:16
相关论文
共 157 条
[21]   CRYSTAL-STRUCTURE OF A P53 TUMOR-SUPPRESSOR DNA COMPLEX - UNDERSTANDING TUMORIGENIC MUTATIONS [J].
CHO, YJ ;
GORINA, S ;
JEFFREY, PD ;
PAVLETICH, NP .
SCIENCE, 1994, 265 (5170) :346-355
[22]   Novel phosphorylation sites of human tumour suppressor protein p53 at Ser20 and Thr18 that disrupt the binding of mdm2 (mouse double minute 2) protein are modified in human cancers [J].
Craig, AL ;
Burch, L ;
Vojtesek, B ;
Mikutowska, J ;
Thompson, A ;
Hupp, TR .
BIOCHEMICAL JOURNAL, 1999, 342 :133-141
[23]  
DEB SP, 1994, ONCOGENE, V9, P1341
[24]   MICE LACKING P21(C/P1/WAF1) UNDERGO NORMAL DEVELOPMENT, BUT ARE DEFECTIVE IN G1 CHECKPOINT CONTROL [J].
DENG, CX ;
ZHANG, PM ;
HARPER, JW ;
ELLEDGE, SJ ;
LEDER, P .
CELL, 1995, 82 (04) :675-684
[25]  
Di Como CJ, 1999, MOL CELL BIOL, V19, P1438
[26]   GAIN OF FUNCTION MUTATIONS IN P53 [J].
DITTMER, D ;
PATI, S ;
ZAMBETTI, G ;
CHU, S ;
TERESKY, AK ;
MOORE, M ;
FINLAY, C ;
LEVINE, AJ .
NATURE GENETICS, 1993, 4 (01) :42-46
[27]   MICE DEFICIENT FOR P53 ARE DEVELOPMENTALLY NORMAL BUT SUSCEPTIBLE TO SPONTANEOUS TUMORS [J].
DONEHOWER, LA ;
HARVEY, M ;
SLAGLE, BL ;
MCARTHUR, MJ ;
MONTGOMERY, CA ;
BUTEL, JS ;
BRADLEY, A .
NATURE, 1992, 356 (6366) :215-221
[28]   DEFINITION OF A CONSENSUS BINDING-SITE FOR P53 [J].
ELDEIRY, WS ;
KERN, SE ;
PIETENPOL, JA ;
KINZLER, KW ;
VOGELSTEIN, B .
NATURE GENETICS, 1992, 1 (01) :45-49
[29]   Exclusion of a p53 germline mutation in a classic Li-Fraumeni syndrome family [J].
Evans, SC ;
Mims, B ;
McMasters, KM ;
Foster, CJ ;
deAndrade, M ;
Amos, CI ;
Strong, LC ;
Lozano, G .
HUMAN GENETICS, 1998, 102 (06) :681-686
[30]   THE MDM-2 ONCOGENE CAN OVERCOME WILD-TYPE P53 SUPPRESSION OF TRANSFORMED-CELL GROWTH [J].
FINLAY, CA .
MOLECULAR AND CELLULAR BIOLOGY, 1993, 13 (01) :301-306